Linked Life Data

7390386

Source:http://linkedlifedata.com/resource/pubmed/id/7390386

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
18
pubmed:dateCreated
1980-9-23
pubmed:abstractText
A total of 98 patients selected and classified into type IIa and IIb hyperlipoproteinemia according to Fredrickson and Lees (1965) were pre-treated for 6 months with a commercially available combination product (containing clofibrate and nicotinic acid). After randomization this pre-treatment was followed by a further 8 week-treatment with the comparison product (group I = 49 patients) or by a change-over to Lipo-Merz retard (group II = 49 patients). Lipo-Merz retard was administered in a dosage of one capsule/day, the combination product in a dosage of one capsule three times daily. In group I the serum cholesterol and serum triglyceride values achieved by the pre-treatment could be lowered by an average of 4%. In group II the reductions were 4% and 6%, respectively. Toleration was good in both groups.
pubmed:language
ger
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0015-8178
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
98
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
(718-20)
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1980
pubmed:articleTitle
[Therapy of lipoproteinemia. Comparison between Lipo-Merz retard and a commercial combination drug].
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, English Abstract, Randomized Controlled Trial